Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Somnomed Limited ( (AU:SOM) ) has shared an announcement.
SomnoMed Limited announced a change in the director’s interest, with Benjamin Gisz acquiring 200,000 options, increasing his total to 685,000 options. This change, approved at the Annual General Meeting, reflects ongoing adjustments in the company’s leadership holdings, potentially influencing investor perceptions and the company’s strategic direction.
The most recent analyst rating on (AU:SOM) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on Somnomed Limited stock, see the AU:SOM Stock Forecast page.
More about Somnomed Limited
SomnoMed Limited operates in the healthcare industry, focusing on the development and distribution of oral appliances for the treatment of sleep-related disorders, particularly obstructive sleep apnea.
Average Trading Volume: 373,921
Technical Sentiment Signal: Buy
Current Market Cap: A$176.7M
See more insights into SOM stock on TipRanks’ Stock Analysis page.